10: BioPorto enters into an agreement with Wiener Lab Group – Status for the distribution of The NGAL Test
June 01 2012
Announcement no. 10
BioPorto has entered into an agreement concerning the bulk purchase, packaging and distribution of NGAL test reagent for Wiener Lab Group’s own analyzers in Latin America. Wiener Lab Group has existed for more than 50 years and is a market leader in analyzers for small and medium-sized laboratories in core Latin American markets, such as Brazil and Argentina. Wiener Lab Group has commenced the registration process for the purpose of obtaining certification of an NGAL assay in Argentina and will subsequently register and market the assay in the rest of Latin America.
BioPorto’s sales strategy for its proprietary The NGAL Test is based on establishing sales channels through local distributors and through global and regional suppliers of analyzers. Since the launch of The NGAL Test, several of the most important suppliers of analyzers have expressed an interest in working together on distributing the immunoassay. Negotiations with several of the biggest of these players concerning access to BioPorto’s The NGAL Test are in progress. At the same time, BioPorto is continuing to develop its national distribution networks, which already cover the most important markets in Europe and the BRIC countries.
The kidney biomarker NGAL
Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.